Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares, NIS 1.80 par value per share
-
Shares outstanding
-
5,591,387
-
Total 13F shares
-
5,585
-
Share change
-
+5,584
-
Total reported value
-
$38,313
-
Price per share
-
$6.86
-
Number of holders
-
9
-
Value change
-
+$38,306
-
Number of buys
-
8
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q3 2024
As of 30 Sep 2024,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,585 shares.
The largest 9 holders included
UBS Group AG, Tower Research Capital LLC (TRC), MORGAN STANLEY, WELLS FARGO & COMPANY/MN, Federation des caisses Desjardins du Quebec, OSAIC HOLDINGS, INC., Allworth Financial LP, ZRC WEALTH MANAGEMENT, LLC, and BNP PARIBAS FINANCIAL MARKETS.
This page lists
9
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.